| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/16/2023 | 37.69% | Morgan Stanley | $225 → $220 | Upgrades | Equal-Weight → Overweight |
| 10/09/2023 | 114.67% | JMP Securities | → $343 | Reiterates | Market Outperform → Market Outperform |
| 10/05/2023 | 48.95% | RBC Capital | → $238 | Reiterates | Outperform → Outperform |
| 10/05/2023 | 40.82% | Oppenheimer | $250 → $225 | Maintains | Outperform |
| 09/29/2023 | 18.91% | DA Davidson | → $190 | Initiates Coverage On | → Neutral |
| 08/18/2023 | 48.95% | RBC Capital | → $238 | Reiterates | Outperform → Outperform |
| 08/18/2023 | 114.67% | JMP Securities | → $343 | Reiterates | Market Outperform → Market Outperform |
| 08/15/2023 | 111.54% | Citigroup | $278 → $338 | Maintains | Buy |
| 07/26/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 06/14/2023 | 114.67% | JMP Securities | → $343 | Reiterates | Market Outperform → Market Outperform |
| 06/07/2023 | 48.95% | RBC Capital | → $238 | Reiterates | Outperform → Outperform |
| 05/31/2023 | 52.71% | Mizuho | → $244 | Initiates Coverage On | → Buy |
| 05/12/2023 | 43.95% | Wedbush | $250 → $230 | Maintains | Outperform |
| 05/12/2023 | 47.08% | Jefferies | $260 → $235 | Maintains | Buy |
| 05/10/2023 | 73.99% | Citigroup | $277 → $278 | Maintains | Buy |
| 02/24/2023 | 73.36% | Citigroup | $301 → $277 | Maintains | Buy |
| 01/17/2023 | 42.07% | Piper Sandler | $222 → $227 | Upgrades | Neutral → Overweight |
| 11/11/2022 | 40.82% | Morgan Stanley | $215 → $225 | Maintains | Equal-Weight |
| 11/11/2022 | 62.72% | Citigroup | $254 → $260 | Maintains | Buy |
| 11/01/2022 | 58.97% | Citigroup | $275 → $254 | Maintains | Buy |
| 10/11/2022 | 34.56% | Morgan Stanley | $235 → $215 | Maintains | Equal-Weight |
| 08/25/2022 | 47.7% | Piper Sandler | → $236 | Initiates Coverage On | → Neutral |
| 08/22/2022 | 56.47% | Wedbush | $220 → $250 | Maintains | Outperform |
| 08/19/2022 | 72.11% | JP Morgan | $260 → $275 | Maintains | Overweight |
| 08/19/2022 | 65.85% | RBC Capital | $240 → $265 | Maintains | Outperform |
| 07/26/2022 | 77.12% | Barclays | $356 → $283 | Maintains | Overweight |
| 07/14/2022 | 47.08% | Morgan Stanley | $260 → $235 | Maintains | Equal-Weight |
| 05/13/2022 | 50.21% | RBC Capital | $365 → $240 | Maintains | Outperform |
| 02/22/2022 | 62.72% | Morgan Stanley | $315 → $260 | Maintains | Equal-Weight |
| 02/18/2022 | 100.28% | Jefferies | $350 → $320 | Maintains | Buy |
| 12/16/2021 | 97.15% | Morgan Stanley | → $315 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 114.67% | JMP Securities | $302 → $343 | Maintains | Market Outperform |
| 08/06/2021 | 103.4% | RBC Capital | $300 → $325 | Maintains | Outperform |
| 07/07/2021 | 87.76% | RBC Capital | → $300 | Upgrades | Sector Perform → Outperform |
| 06/09/2021 | 62.72% | JP Morgan | → $260 | Upgrades | Neutral → Overweight |
| 05/26/2021 | 81.5% | Morgan Stanley | $338 → $290 | Maintains | Overweight |
| 05/14/2021 | 85.25% | Citigroup | $312 → $296 | Maintains | Buy |
| 02/22/2021 | 111.54% | Morgan Stanley | $334 → $338 | Maintains | Overweight |
| 02/19/2021 | 111.54% | Morgan Stanley | $334 → $338 | Maintains | Overweight |
| 02/19/2021 | 78.37% | Wedbush | $275 → $285 | Maintains | Outperform |
| 02/11/2021 | 81.5% | Oppenheimer | → $290 | Assumes | → Outperform |
| 01/29/2021 | 106.53% | Barclays | $246 → $330 | Upgrades | Equal-Weight → Overweight |
| 12/17/2020 | 109.04% | Morgan Stanley | $230 → $334 | Upgrades | Equal-Weight → Overweight |
| 11/13/2020 | 43.95% | Morgan Stanley | $212 → $230 | Maintains | Equal-Weight |
| 11/13/2020 | 81.5% | Rosenblatt | $265 → $290 | Reiterates | → Buy |
| 11/13/2020 | 72.11% | Wedbush | $250 → $275 | Maintains | Outperform |
| 11/03/2020 | 75.24% | B of A Securities | → $280 | Initiates Coverage On | → Buy |
| 10/22/2020 | 65.85% | Rosenblatt | $260 → $265 | Maintains | Buy |
| 08/07/2020 | 32.68% | Morgan Stanley | $156 → $212 | Maintains | Equal-Weight |
| 06/26/2020 | 7.65% | JP Morgan | → $172 | Downgrades | Neutral → Underweight |
| 06/18/2020 | 25.17% | Oppenheimer | $180 → $200 | Maintains | Outperform |
| 05/15/2020 | -2.37% | Morgan Stanley | $144 → $156 | Maintains | Equal-Weight |
| 05/11/2020 | -9.88% | Morgan Stanley | $133 → $144 | Maintains | Equal-Weight |
| 03/25/2020 | -16.76% | Morgan Stanley | $173 → $133 | Maintains | Equal-Weight |
| 02/14/2020 | 8.27% | Morgan Stanley | $160 → $173 | Maintains | Equal-Weight |
| 02/14/2020 | 25.17% | Wedbush | $185 → $200 | Maintains | Outperform |
| 02/14/2020 | 22.04% | Rosenblatt | $187 → $195 | Maintains | Buy |
| 02/14/2020 | 20.79% | Citigroup | $156 → $193 | Maintains | Neutral |
| 01/27/2020 | 2.02% | JP Morgan | → $163 | Downgrades | Overweight → Neutral |
| 11/27/2019 | 6.4% | Oppenheimer | $166 → $170 | Maintains | Outperform |
| 11/18/2019 | -6.12% | Morgan Stanley | $140 → $150 | Maintains | Equal-Weight |
| 11/15/2019 | 6.4% | Wedbush | $165 → $170 | Maintains | Outperform |
| 09/04/2019 | 17.04% | Rosenblatt | → $187 | Initiates Coverage On | → Buy |
| 08/09/2019 | 15.78% | JMP Securities | $164 → $185 | Maintains | Market Outperform |
| 05/17/2019 | -14.26% | Citigroup | $117 → $137 | Maintains | Neutral |
| 05/17/2019 | 2.64% | JMP Securities | $140 → $164 | Maintains | Market Outperform |
| 05/17/2019 | -19.89% | Morgan Stanley | $117 → $128 | Maintains | Equal-Weight |
| 04/24/2019 | -6.12% | Barclays | $124 → $150 | Maintains | Equal-Weight |
| 04/18/2019 | -6.12% | JP Morgan | $125 → $150 | Upgrades | Neutral → Overweight |
| 04/17/2019 | -21.77% | DA Davidson | $110 → $125 | Maintains | Neutral |
| 04/17/2019 | -9.25% | Oppenheimer | $125 → $145 | Maintains | Outperform |
| 01/07/2019 | -26.77% | Morgan Stanley | $107 → $117 | Maintains | Equal-Weight |
| 10/19/2018 | -18.64% | Wedbush | → $130 | Initiates Coverage On | → Outperform |
What is the target price for NICE (NICE)?
The latest price target for NICE (NASDAQ: NICE) was reported by Morgan Stanley on October 16, 2023. The analyst firm set a price target for $220.00 expecting NICE to rise to within 12 months (a possible 37.69% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NICE (NICE)?
The latest analyst rating for NICE (NASDAQ: NICE) was provided by Morgan Stanley, and NICE upgraded their overweight rating.
When is the next analyst rating going to be posted or updated for NICE (NICE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NICE, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NICE was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
Is the Analyst Rating NICE (NICE) correct?
While ratings are subjective and will change, the latest NICE (NICE) rating was a upgraded with a price target of $225.00 to $220.00. The current price NICE (NICE) is trading at is $159.78, which is out of the analyst's predicted range.